(Alliance News) - GSK PLC on Friday said its drug Blenrep has received a "positive opinion" from the European Medicines Agency's Committee for Medicinal Products for Human Use.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s (LSE: GSK) Blenrep (belantamab ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the ...

GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, May 20, 2025, 12:00 Hrs [IST] GSK plc announced ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) announced Monday the approval of Blenrep combinations by Japan's Ministry of Health, Labour and Welfare or MHLW for the treatment of adults with ...

GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or ...